Visualising neuroinflammation in chronic fatigue syndrome patients

Completed

Conditions: vermoeidheidssyndroom
chronic fatigue syndrome

Registration Number: NL-OMON43880

Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 30

Inclusion Criteria

Control subjects
> Female, between 18 and 60 years old;
> Neighbourhood control, i.e. live in the same neighbourhood as the CSF patient;CFS patients
> CDC-diagnosed CFS-patients;
> Female, between 18 and 55 years old;
> Score of *40on the subscale fatigue severity of the CIS (Checklist Individual Strength);
> Marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of *700.;Patients with Q-fever induced CFS
> Diagnosis according to the Dutch guideline on QFS [RIVM, Q-koortsvermoeidheidssyndroom] ;
> Female, between 18 and 60 years old ;
> Score of *40 on the subscale fatigue severity of the CIS (Checklist Individual Strength);
> Marked functional impairment assessed with the Sickness Impact Profile (SIP-8) and operationalised as a total score of *700.

Exclusion Criteria

All subjects
> Women who are pregnant;
> Women who intend to get pregnant during the study;
> Use or having used psychotropic medication in the past six months;
> Alcohol or substance abuse in the past 3 months;
> Use or have used doxycycline in the past six months;
> Evident somatic/psychiatric co-morbidity;
> Presence of materials in the body that can be magnetized and cannot be removed;
> Participation in a scientific research study during the past year involving radiation.;CFS patients and control subjects
> History of Q-fever;
> Vaccinated for Q-fever

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the [11C]PK11195 binding potential in the brain.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters are MRI measurements, fatigue severity using the CIS<br /><br>fatigue questionnaire and peripheral cytokine concentrations.</p><br>